Omnicell Com - OMCL STOCK NEWS

Omnicell (NASDAQ: OMCL) has appointed Perry A. Genova, PhD as Senior Vice President and Chief Technology Officer, effective March 31, 2025. Dr. Genova brings over 25 years of experience in product development, strategic planning, and regulatory compliance across medical device, pharmaceutical, and life sciences industries.

In his new role, Dr. Genova will spearhead Omnicell's technology strategy, focusing on addressing medication and supply management challenges across care settings to advance the company's vision of the Autonomous Pharmacy. According to Executive Vice President and COO Nnamdi Njoku, Genova's entrepreneurial mindset is expected to play a important role in advancing Omnicell's multi-year, outcome-centric growth strategy.

Omnicell (NASDAQ:OMCL) announced that Executive Vice President and Chief Financial Officer Nchacha Etta will step down from his position, effective September 15, 2025, or until a successor is named. The company has initiated a national search for his replacement.

Etta, who joined Omnicell in mid-2023, will continue in his role during the transition period. Chairman, President, CEO, and founder Randall Lipps acknowledged Etta's contributions in integrating recent acquisitions and implementing operational efficiencies during challenging industry conditions.

The company has also reiterated its first quarter and full year 2025 guidance, previously announced in their Q4 2024 earnings release on February 6, 2025. Omnicell maintains its focus on executing strategic priorities and driving long-term revenue growth while supporting customers in achieving enhanced clinical and operational outcomes.

Omnicell (NASDAQ:OMCL) reported strong Q4 2024 financial results, with total revenues of $307 million, up 19% from Q4 2023. However, full-year 2024 revenues decreased 3% to $1.112 billion compared to 2023.

The company achieved GAAP net income of $16 million ($0.34 per diluted share) in Q4 2024, compared to a loss of $14 million in Q4 2023. Full-year 2024 GAAP net income was $13 million ($0.27 per diluted share).

Total bookings for 2024 reached $923 million, an 8% increase from 2023, driven by XT Series upgrades. The company's balance sheet showed $369 million in cash and cash equivalents, with total debt of $341 million. Omnicell issued $172.5 million in convertible senior notes and provided 2025 guidance projecting total revenues between $1.105-1.155 billion.

Omnicell (Nasdaq:OMCL), a company focused on transforming pharmacy and nursing care delivery models, has announced it will release its fourth quarter and full year 2024 financial results before market open on Thursday, February 6, 2025.

The company will host a conference call and webcast to discuss these results at 8:30 a.m. ET on the same day. Interested parties can join via phone using the numbers (800) 715-9871 (U.S.) or (646) 307-1963 (international) with Conference ID 2515873. A live and archived webcast will be available through Omnicell's Investor Relations website.

Omnicell (OMCL), a company focused on pharmacy care delivery transformation, has announced its upcoming presentation at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Wednesday, January 15, 2025, at 1:30 p.m. PT.

Interested parties can access both live and archived versions of the presentation through the company's investor relations website at their events and presentations page. This participation in one of healthcare industry's premier conferences demonstrates Omnicell's continued engagement with the investment community.

Omnicell (Nasdaq:OMCL) has announced OmniSphere, a next-generation, cloud native software workflow engine and data platform designed to integrate enterprise robotics and smart devices for medication management. The platform aims to provide state-of-the-art security, improved productivity through single-point access, and enterprise-wide medication inventory visibility.

The company also revealed that its XT Amplify program solutions, including MedChill and XTExtend, are OmniSphere-ready. Additionally, MedChill now integrates with Follett refrigerators for temperature-controlled medications. Omnicell has also developed new DSCSA interface options with TrackTraceRX and LSPedia for its Central Pharmacy Manager software.

Omnicell (Nasdaq: OMCL), a leading pharmacy care delivery model transformation company, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The presentation is scheduled for Tuesday, December 3, 2024, at 2:00 p.m. ET. Both live and archived versions of the presentation will be accessible to interested parties through Omnicell's investor relations website in the events and presentations section.

Omnicell has announced the pricing of $150 million of 1.00% Convertible Senior Notes due 2029. The notes will mature on December 1, 2029, with interest payable semiannually at 1.00% per annum. The initial conversion rate is 17.4662 shares per $1,000 principal amount, equivalent to $57.25 per share. The company expects net proceeds of approximately $144.2 million, which will be used to repurchase $400 million of existing 2025 notes and fund convertible note hedge transactions. The offering includes additional options for purchasers and various hedging arrangements to manage potential dilution.

Omnicell (NASDAQ: OMCL) announces plans to offer $150 million of Convertible Senior Notes due 2029 in a private placement to qualified institutional buyers. The company will grant initial purchasers an option for an additional $22.5 million. The notes will be senior unsecured obligations with semiannual interest payments. Omnicell plans to use the proceeds to fund convertible note hedge transactions and repurchase up to $400 million of its outstanding 0.25% Convertible Senior Notes due 2025.